PERSPECTIVE THERAPEUTICS INC (CATX)
US46489V3024 - Common Stock
Overall CATX gets a fundamental rating of 3 out of 10. We evaluated CATX against 572 industry peers in the Biotechnology industry. While CATX seems to be doing ok healthwise, there are quite some concerns on its profitability. CATX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CATX had negative earnings in the past year.
In the past year CATX has reported a negative cash flow from operations.
CATX had negative earnings in each of the past 5 years.
In the past 5 years CATX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -20.95%, CATX is in the better half of the industry, outperforming 76.46% of the companies in the same industry.
Looking at the Return On Equity, with a value of -23.71%, CATX belongs to the top of the industry, outperforming 82.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.95% | ||
| ROE | -23.71% | ||
| ROIC | N/A |
ROA(3y)-21.2%
ROA(5y)-31.63%
ROE(3y)-26.25%
ROE(5y)-41.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CATX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CATX has less shares outstanding
CATX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, CATX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.46 indicates that CATX is not a great score, but indicates only limited risk for bankruptcy at the moment.
CATX has a better Altman-Z score (2.46) than 74.87% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that CATX is not too dependend on debt financing.
CATX's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. CATX outperforms 45.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.46 |
ROIC/WACCN/A
WACC10.89%
2.3 Liquidity
A Current Ratio of 27.73 indicates that CATX has no problem at all paying its short term obligations.
CATX's Current ratio of 27.73 is amongst the best of the industry. CATX outperforms 96.99% of its industry peers.
CATX has a Quick Ratio of 27.73. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
CATX has a better Quick ratio (27.73) than 96.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 27.73 | ||
| Quick Ratio | 27.73 |
3. Growth
3.1 Past
CATX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
Looking at the last year, CATX shows a small growth in Revenue. The Revenue has grown by 7.46% in the last year.
CATX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.80% yearly.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
Revenue 1Y (TTM)7.46%
Revenue growth 3Y13.89%
Revenue growth 5Y17.8%
Sales Q2Q%-83.11%
3.2 Future
Based on estimates for the next years, CATX will show a very negative growth in Earnings Per Share. The EPS will decrease by -108.25% on average per year.
CATX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.26% yearly.
EPS Next Y-2619.93%
EPS Next 2Y-315.34%
EPS Next 3Y-180.72%
EPS Next 5Y-108.25%
Revenue Next Year-25.94%
Revenue Next 2Y-64.5%
Revenue Next 3Y-59.57%
Revenue Next 5Y5.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CATX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CATX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CATX's earnings are expected to decrease with -180.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-315.34%
EPS Next 3Y-180.72%
5. Dividend
5.1 Amount
No dividends for CATX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PERSPECTIVE THERAPEUTICS INC
NYSEARCA:CATX (1/14/2025, 8:04:02 PM)
After market: 3.2003 +0 (+0.01%)3.2
-0.2 (-5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners57.25%
Inst Owner Change0%
Ins Owners3.04%
Ins Owner Change0.04%
Market Cap215.78M
Analysts81.25
Price Target16.83 (425.94%)
Short Float %16.65%
Short Ratio5.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.96%
Min EPS beat(2)15.95%
Max EPS beat(2)15.97%
EPS beat(4)3
Avg EPS beat(4)-25.35%
Min EPS beat(4)-135.27%
Max EPS beat(4)15.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-26.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.35%
EPS NY rev (1m)0%
EPS NY rev (3m)3.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)123.56%
Revenue NY rev (1m)18.64%
Revenue NY rev (3m)23.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 48.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.63 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.47
EYN/A
EPS(NY)-0.86
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.07
BVpS5.06
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.95% | ||
| ROE | -23.71% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-21.2%
ROA(5y)-31.63%
ROE(3y)-26.25%
ROE(5y)-41.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 710.86% | ||
| Cap/Sales | 232.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 27.73 | ||
| Quick Ratio | 27.73 | ||
| Altman-Z | 2.46 |
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)140.96%
Cap/Depr(5y)163.53%
Cap/Sales(3y)27.56%
Cap/Sales(5y)18.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.5%
EPS Next Y-2619.93%
EPS Next 2Y-315.34%
EPS Next 3Y-180.72%
EPS Next 5Y-108.25%
Revenue 1Y (TTM)7.46%
Revenue growth 3Y13.89%
Revenue growth 5Y17.8%
Sales Q2Q%-83.11%
Revenue Next Year-25.94%
Revenue Next 2Y-64.5%
Revenue Next 3Y-59.57%
Revenue Next 5Y5.26%
EBIT growth 1Y-161%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.85%
EBIT Next 3Y-47.76%
EBIT Next 5YN/A
FCF growth 1Y-196.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.31%
OCF growth 3YN/A
OCF growth 5YN/A